Centene (CNC) Stock Forecast & Price Target

Centene is supported by a broad recovery across its core businesses, led by three consecutive quarters of Medicaid HBR improvement, a 1Q26 adjusted EPS beat, and raised 2026 adjusted EPS guidance to greater than $3.40 after a difficult 2025. Its 12.4 million Medicaid members across 30 states, 3.58 million Marketplace members at 1Q26, and improving Medicare and PDP trends create scale, revenue visibility, and multiple pathways to margin restoration, while constructive state rate dialogue and a potential Marketplace risk-adjustment receivable add near-term upside. Although the shares have rallied sharply and are already pricing in much of the earnings rebound, the combination of disciplined execution, pricing actions, and structural advantages in managed Medicaid and Duals supports a positive fundamental outlook.

Centene is facing a fundamentally fragile earnings recovery because its 2025 dislocation was severe, with adjusted EPS roughly $5 below the original >$7.25 guide, a 6.7 billion goodwill impairment in 3Q25, and a 2025 pre-tax margin near -1% versus a 5% to 7.5% target range. Its core government-funded businesses remain pressured by structural policy and utilization headwinds: the OBBBA could cut Medicaid spending by about $910 billion over the next decade, Medicaid membership is expected to decline about 6% from year-end 2025 to year-end 2026, and elevated behavioral health and Marketplace morbidity continue to strain pricing accuracy. Even with three straight quarters of Medicaid HBR improvement and 1Q26 adjusted SG&A down to 7.6%, management still expects negative margins in 2026, sees Medicare MA HBRs elevated, and has not re-anchored long-term margin targets amid policy uncertainty.